Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

Area of Science:

• Oncology
• Proteomics
• Bioinformatics

Background:

• Cancer cell lines are crucial for mechanistic studies and drug development.
• A lack of comprehensive protein expression data linked to genomic, transcriptomic, and drug screening data across numerous cell lines hinders research.
• Existing datasets often lack integrated multi-omics and drug sensitivity information.

Purpose of the Study:

• To generate a large-scale dataset of protein expression in cancer cell lines.
• To investigate the utility of protein expression data, particularly phosphoproteins, in predicting drug sensitivity.
• To develop a user-friendly bioinformatic resource for accessing and analyzing this data.

Main Methods:

• Utilized reverse-phase protein arrays (RPPA) to measure the expression levels of approximately 230 cancer-related proteins.
• Collected data from over 650 independent cancer cell lines.
• Integrated protein expression data with publicly available genomic, transcriptomic, and drug screening data.

Main Results:

• The generated dataset successfully recapitulates the impact of mutated pathways on protein expression, mirroring findings in patient samples.
• Protein and phosphoprotein expression levels provide predictive information for drug sensitivity that is not captured by messenger RNA (mRNA) levels.
• Developed the 'MCLP' ( a user-friendly bioinformatic resource for the biomedical research community.

Conclusions:

• Large-scale protein expression profiling of cancer cell lines offers valuable insights into cancer mechanisms and drug responses.
• Proteomic data, especially phosphoproteomic data, significantly enhances the prediction of drug sensitivity compared to transcriptomic data alone.
• The MCLP resource facilitates the use of this integrated dataset for advancing cancer research and drug discovery.